德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications 2022-03-02 08:47
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037 2022-02-07 08:30
Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference 2022-01-05 12:50
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors 2021-12-30 09:51
First Patient Dosed in Australia in ATG-101 First-in-Human Trial 2021-12-20 11:01
First Patient Dosed in Australia in ATG-101 First-in-Human Trial 2021-12-20 10:56
Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma 2021-12-17 22:27
Antengene and XtalPi Announce AI-Driven R&D Collaboration 2021-12-16 16:30
Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting 2021-12-14 18:00
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors 2021-12-13 08:30
Antengene Included in the MSCI Global Small Cap Indexes - MSCI China Index Constituent Stocks 2021-11-26 11:34
Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day 2021-11-19 13:00
Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma 2021-11-19 08:30
Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021 2021-11-15 08:25
Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting 2021-11-09 16:30
Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma 2021-11-02 08:30
Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma 2021-11-01 08:40
Antengene to Host its First R&D Days on November 16 and November 18, 2021 2021-10-25 20:00
Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates 2021-10-21 16:00
Antengene to Present Data of Its PD-L1/4-1BB Bispecific Antibody ATG-101 and ERK1/2 Inhibitor ATG-017 at SITC 2021 2021-10-15 13:33
1 3 4 5 6 7 9